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A B S T R A C TObjectives: The Testing Morbidities Index (TMI) was developed to
measure the effects of any diagnostic or screening procedure on
health-related quality of life (HRQOL); it includes seven domains
incorporating mental and physical aspects before, during, and after
testing. To add to prior work on the validity of the TMI classiﬁcation,
responsiveness of a summated scale version was evaluated in 71
colonoscopy patients. Further data on construct validity were also
obtained. Methods: Patients enrolled in the study when scheduling
colonoscopy days to weeks beforehand. The baseline survey included
the EuroQol ﬁve-dimensional (EQ-5D) questionnaire with ﬁve levels in
each attribute (EQ-5D-5L questionnaire) and its visual analogue scale
(VAS) assessment (EQ-VAS), the Short Form 12 version 2 (SF-12v2)
component summary scores and six-dimensional health state short-
form (derived from the short-form 12v2 health survey [SF-6D] util-
ities), and an original construct-speciﬁc VAS (CS-VAS) for usual
HRQOL using utility scale anchors. The TMI’s highest possible sum-
mated score (all best levels) served as its baseline. Survey data were
generally obtained by telephone interview. A postprocedure surveysee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.07.008
@mgh-ita.org.
ndence to: J. Shannon Swan, MGH Institute for Tecwas given to patients after colonoscopy and interviews conducted as
soon as possible after the day of the procedure. The postprocedure
survey included the SF-12v2/SF-6D, EQ-5D questionnaire instruments,
TMI items, and a CS-VAS incorporating the overall HRQOL effects of
colonoscopy. Results: Standardized response means showed greatest
responsiveness by the TMI (1.52) followed by the CS-VAS instru-
ments (0.42). The EQ-5D-5L questionnaire, the EQ-VAS, and the SF-12
component summaries were unresponsive, and the SF-6D was min-
imally responsive (0.05). Correlation of the post–CS-VAS with the
TMI was substantial (r ¼ 0.52), suggesting TMI construct validity.
Moderate to strong correlation of the baseline CS-VAS with standard
indexes was observed (r ¼ 0.54–0.81). Conclusion: The TMI appears
responsive and exhibits further evidence of construct validity.
Keywords: health-related quality of life, preference-based indexes,
psychometrics, responsiveness.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
There has been a recent call for more thorough evaluations of the
various effects of testing on patient outcomes, and health-related
quality-of-life (HRQOL) measurement seems appropriate to
address some issues [1]. For example, screening colonoscopy is
a widely used test but one for which many hesitate to participate
because of concerns about the discomfort of bowel preparation
before the procedure, pain during the procedure, and potential
complications such as colon perforation [2]. Usual HRQOL meas-
urement, however, is applied in chronic states by applying direct
preferences, preference-based indexes, or summated scale pro-
ﬁles [3–5].
For short-term quality-of-life measurement, one could con-
sider applying a generic index for a short period of time, or use
modiﬁcations of direct preference methods [6]. With indexes,
concerns include recall times of 1 week or a month in some
instruments, which may not detect short-term events, as well as
domain coverage that may not be sensitive for testing. For direct
choice–based assessments, a major issue with standard gamble
and time trade-off (TTO) is that a short-term state is beingjuxtaposed with death, which discourages any trade-off or risk.
This ceiling effect may occur despite the presence of disutility
from the health state [6]. “Chained” versions of direct standard
gamble or TTO could be considered as alternatives and are
consistent with the quality-adjusted life-year theory. Relevant
quality-adjusted life-year theory axioms include 1) constant
proportional trade-off, 2) risk neutrality across life-years, and 3)
independence of preferences for health regardless of life expect-
ancy. As Wright et al. [6] have noted, proportional trade-off is the
main concern because the duration of a temporary health state
may affect valuation results [6]. Chained methods have two
stages, where an anchor state worse than a temporary state of
interest is valued between perfect health and death, followed by
assessment of the temporary state between the anchor state and
perfect health [7,8]. Chained approaches are generally workable
for health states that are not being evaluated for trade-offs of a
year or more in assessments but are infeasible for short-term
events such as testing and screening. For example, in a chained
TTO, one cannot realistically imagine having the experience of
colonoscopy for 1 month, while the effects of a “longer” short-
term event such as chemotherapy could be visualized this wayociety for Pharmacoeconomics and Outcomes Research (ISPOR).
hnology Assessment, 101 Merrimac Street, 10th Floor, Boston, MA
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applications but remain controversial in terms of validity, though
advocated recently by Parkin and Devlin [9–12].
Direct methods have been attempted for measuring medical
testing disutility/morbidity. Variants on more typical choice-based
techniques include Willingness to Give up Time [13] and a TTO
variant called the waiting trade-off (WTO). In the WTO, a period of
time is derived that could be implemented as a disutility toll, using a
typical search pattern to indifference. The objective in the WTO
search pattern is to ﬁnd where the patient is indifferent to waiting
for the results of an ideal test with no morbidity as opposed to
having treatment now and undergoing a potentially noxious real
test. The longer one waits, the greater is the disutility. This period of
time is quality-adjusted by multiplying the waiting time by the
difference in chronic or usual utility for the disease of interest and
usual baseline health utility. This technique has been shown to be
conceptually equivalent to the chained TTO [14] but makes more
realistic sense for testing. Nonetheless, the WTO has disadvantages,
including the respondent burden of any choice-based task, the
potential complexity of waiting as a construct, and violation of
proportional trade-off as in other adapted short-term TTOmeasures
[6]. VASs have been used in multiple testing applications [14–16].
Given the motivations described earlier and limitations of
direct methods, indexes may be advantageous while providingTable 1 – Multiattribute health classiﬁcation and survey
Attribute
Pain/discomfort preparing for the test
Howmuch pain or discomfort was involved with preparing for the test?
changes, procedures, or medications that may have been required b
Fear/anxiety before the test
Based on what you knew about this particular test, how much fear or
having the test before the test?
Pain/discomfort during the test
Thinking about this test, how much pain or discomfort did you exper
Embarrassment during the test
How much embarrassment, if any, did you actually feel during the tes
revealing parts of your body, movements of the body, or other aspec
feel awkward or uncomfortable)?
Fear/anxiety during the test
How much fear or anxiety did you feel during this test experience?
Mental function after the test
Thinking about the ability to do your daily activities after this test, how
had with your mental function or state of mind (for example fear, a
difﬁculty concentrating, etc.)? This may be difﬁcult for you to separ
patient. However as best as you can, try to focus on the particular pr
caused.
Physical function after the test
Thinking about the ability to do your daily activities after this test, ho
problems you had with your physical function (for example working
back, neck, and arms, etc.)?proﬁle information from individual attribute scores. The Testing
Morbidities Index (TMI) classiﬁcation was developed to assess the
HRQOL impact of testing. Domains/attributes of the TMI are
based on a theoretical model of testing HRQOL in which psycho-
logical and physical domains of the HRQOL are relevant to a
variable extent leading up to the test, during the test, and
afterward (Table 1). Prior pilot work suggests evidence of con-
struct and content validity of this approach. Psychometric anal-
ysis showed that the TMI domains were correlated with barriers
to testing and preliminary evidence of known-groups validity
was seen [17]. Preference-based and psychometric scoring are
both reasonable goals for the TMI. Psychometric instruments
allow for wider applications and could be more responsive than a
preference-based version [18,19], but preferences may be useful
for economic analysis. The work presented here used the sum-
mated scale version of the TMI.
Screening colonoscopy provides a good opportunity for fur-
ther evaluation of the TMI, given its importance in health
maintenance contrasted with its presumed morbidity from the
viewpoint of patients. In a recent large study, the most com-
monly voiced reason to not participate in colonoscopy screening
was the unpleasantness of the examination [20]. Colonoscopy
requires patients to undergo purging of colonic contents, usually
done the day before the procedure, when patients are also put onitems: Testing Morbidities Index
Description of level
1. No pain or discomfort (or, not
applicable)This question refers to any diet
efore the actual test. 2. Mild pain or discomfort
3. Moderate pain or discomfort
4. Severe pain or discomfort
5. Extreme pain or discomfort
1. No fear or anxiety
anxiety did you have about 2. Mild fear or anxiety
3. Moderate fear or anxiety
4. Severe fear or anxiety
5. Extreme fear or anxiety
1. No pain or discomfort
ience while it was happening? 2. Mild pain or discomfort
3. Moderate pain or discomfort
4. Severe pain or discomfort
5. Extreme pain or discomfort
1. No embarrassment
t experience (for example
ts that may have caused you to
2. Mild embarrassment
3. Moderate embarrassment
4. Severe embarrassment
5. Extreme embarrassment
1. No fear or anxiety
2. Mild fear or anxiety
3. Moderate fear or anxiety
4. Severe fear or anxiety
5. Extreme fear or anxiety
1. No problems
serious were any problems you
nxiety, worry, depression, and
ate from the process of being a
oblems the test itself may have
2. Mild problems
3. Moderate problems
4. Severe problems
5. Extreme problems
1. No problems
w serious were any temporary
, walking, ability to move your
2. Mild problems
3. Moderate problems
4. Severe problems
5. Extreme problems
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 4 6 – 1 0 5 31048a clear liquid diet. A large volume of laxative ﬂuid is consumed,
which causes substantial diarrhea, and should be followed until
the evacuated ﬂuids are relatively clear. Some temporary perianal
tenderness may occur. This procedure is followed so that the
colonoscopist can visualize the walls of the colon completely
from the anus through the proximal end of the colon and its
junction with the small bowel. In addition to the diarrhea, this
preparation process often causes some nausea in patients. The
patient is not allowed to eat or drink anything the morning of the
procedure. Sedation is used for the procedure, and so most
patients do not remember the actual examination. Colonoscopy
can take more than half an hour to perform depending on
difﬁculty with navigating the colon with the ﬁber optic scope,
the need to remove polyps, or the need for biopsies. Afterward,
patients may experience variable residual sedation and are asked
not to drive for the rest of the day. There may be some gas and
mild cramping. Colon perforation during the procedure is uncom-
mon in skilled hands but could require surgery in the unlikely
event it occurred.
The work presented has two main objectives. First, TMI respon-
siveness is reported, as well as ceiling and ﬂoor effects of the TMI
summated scale used in 71 patients who had screening colono-
scopy. First, to assess responsiveness, the focus was on typically
used measures that assess effect size (ES) [21]. Other instruments
are similarly assessed, such as the Short Form 12 version 2 (SF-12v2)
physical and mental component summaries, the six-dimensional
health utility short form (derived from short-form 12v2 health
survey) (SF-6D), the EuroQol ﬁve-dimensional (EQ-5D) questionnaire
with ﬁve levels in each attribute (EQ-5D-5L questionnaire), and the
EQ-5D questionnaire VAS. Also included is an original feeling
thermometer VAS that was designed to capture the baseline
construct as well as the overall effects of colonoscopy, which is
henceforth referred to as the construct-speciﬁc VAS (CS-VAS).
Second, the construct/convergent validity of the TMI was assessed
by its correlation with the CS-VAS assessment postprocedure, and
similarly, the convergent validity of the baseline index assessments
was assessed by their correlation with the baseline CS-VAS
instrument.Methods
Patients
We identiﬁed as potentially eligible for the study English-
speaking patients scheduled for screening colonoscopy during
the period September 2011 through May 2012. Patients were
contacted for the baseline survey by mail, provided with all
instruments including the VASs, and then contacted by tele-
phone and recruited to complete baseline and postprocedure
studies. The postprocedure packet was distributed in person after
the test, and the interview was completed by telephone. Study
eligibility required the willingness to complete both surveys;
patients who did both were paid $10. Only those patients for
whom we have complete baseline and postprocedure data are
included in our analyses.
HRQOL Measurement Instruments
Testing HRQOL is important in peoples’ perceptions but likely
difﬁcult to measure, particularly with existing instruments that
have the issues mentioned in regard to both indexes and direct
techniques as mentioned earlier. Therefore, it is relevant to
evaluate the TMI alongside available measures.
The EQ-5D questionnaire was selected because it has been
used in testing, albeit in a limited way in breast biopsy [22,23].
The EQ-5D questionnaire has pronounced ceiling effects in priorliterature [24–26]. The version used for many years has three
levels in each of ﬁve attributes, allowing for 243 health states. A
utility function was derived from regression modeling by using a
subset of multiattribute health states. The new version was used
that has ﬁve levels per attribute instead of three (EQ-5D-5L), with
its available interim value set [27] provided by the Euroqol Group.
This revision of the EQ-5D questionnaire is expected to address
ceiling effects. Included with the utility function items was a VAS
(EQ-5D VAS) that asked subjects how good or bad their current
health was on the current day. A feeling thermometer was used,
but the scale anchors were “best” and “worst imaginable health
state.” This VAS was felt to be of interest given our baseline and
postcolonoscopy CS-VAS. The EQ-5D questionnaire index uses
present-day recall, which is problematic for encompassing the
entire colonoscopy experience. Thus, the investigators were
motivated to minimize the time lapse until the postprocedure
interview.
The SF-12v2 is a standard quality-of-life measure, derived
from the original short-form 36 health survey. It is used here via
the physical (physical component summary) and mental compo-
nent scale (mental component summary) measures [28,29]. The
SF-6D utility index can be derived from seven items in the SF-12
[30]. The SF-6D has a more optimal ceiling effect than do all
standard indexes with the exception of the Quality of Well-Being
scale [26]. It has a regression modeling approach [30] for its utility
function. The acute recall form (1 week) was used to more
optimally encompass the entire before, during, and after experi-
ence of colonoscopy. The SF-12/SF-6D has not been used in
testing, but given the above aspects, it seemed possible that it
would perform better than the EQ-5D questionnaire. SF-12/SF-6D
procurement and scoring software involved licensing fees
through Quality Metric, Inc.
A direct VAS is important for inclusion as a more construct-
speciﬁc comparator to the TMI (the previously mentioned CS-
VAS). An additional measure is also applicable when there is no
gold standard. De Vet et al. [31] note the usefulness of a “Global
Rating Scale (GRS)” as either a criterion or construct measure.
Such an approach can have high face validity, and the degree of
correlation of the Global Rating Scale or its equivalent with the
measure of interest is favored when a continuous variable is
used. De Vet et al. were referring to a ﬁve-point rating scale, but a
VAS could be used as well. In the current case, the use of the CS-
VAS is also relevant for suggesting the validity of the responsive-
ness calculation for the TMI as discussed below. Furthermore, the
CS-VAS at baseline assessing “usual HRQOL” is helpful for
assessing the validity of results of standard index instruments
at the baseline at least 4 days before the procedure.
Summated scale scoring for the TMI classiﬁcation (Table 1)
was adapted from Tomlinson et al. [32]. Equation 1 was used as
follows to convert one survey’s TMI item responses on a sum-
mated scale from 35 (worst) to 7 (best) to a 0 (worst) to 100 (best)
scale. Each item has equal weight and the response is coded 1 to
5 in variable Li. The denominator value of 4 is the number of
response categories (5 in all items) – 1 (Equation 1).
TMI summated scale¼100 100
7
 
∑
7
i¼1
Li1
4
ð1Þ
Survey Accrual Plan
Baseline
Given the TMI theoretical model, baseline is deﬁned as HRQOL
that is one’s usual state before a testing event of interest. It does
not incorporate morbidity from preparation for the test or anxiety
because of the test. Thus, a baseline was deﬁned from survey
completion, which we aimed to accomplish by telephone
Table 2 – Demographics of screening
colonoscopy sample.
Number of complete interview sets (n) (baseline
and within 4 d postprocedure) 71
Age (y), mean/median
Women 62.1/63.0
Men 62.6/63.5
Gender proportions (%)
Women 38
Men 62
Race/ethnicity (%)
White 93
Black 3
Hispanic 1.4
Other/unknown 2.6
Income ($), mean/median 97,118/67,000
Years of education, mean and median 16
Family history of colorectal cancer (n) 17
Days from procedure to postprocedure
interview, mean/median
2.3/3.0
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 4 6 – 1 0 5 3 1049interview, at least 3 days before bowel preparation. Realizing that
the true baseline is before the procedure was even mentioned to
the patient by the doctor, we evaluated the adequacy of this
baseline assessment by the correlation of the baseline CS-VAS
meant to capture “usual quality of life” with the baseline indexes.
For the EQ-5D-5L questionnaire and SF-12v2, baseline assessment
is otherwise straightforward, with usual completion of surveys.
For the CS-VAS baseline, the wording was as follows, with a
feeling thermometer visual prop used similar to the EQ-5D
questionnaire VAS: “Please rate your usual quality of life on the
scale to the right, on a scale of 0 to 100, with 0 being the value of
death and 100 being the value of perfect health.”
Given the TMI classiﬁcation (Table 1), however, the baseline
deﬁnition for TMI requires modiﬁcation. The TMI has a compre-
hensive experiential perspective. To complete the TMI survey items,
one has to have experienced the entire testing sequence with any
morbidities before, during, and afterward. The TMI classiﬁcation
shows that one can assess responsiveness only in terms of change
from the top of the summated scale. The top of the scale in this
classiﬁcation can only be a state in which the least possible
morbidity has been incurred. This is not to say that perfect health
is being assumed before the testing experience but that no morbid-
ity in terms of testing has been experienced. Similarly, the baseline
that must be assumed is that health state in which all attributes are
at their best level, similar to the “best possible test.” For the TMI
summated scale, this means that the baseline is 7 (all attributes at
level 1) or 100 (from Equation 1) for all patients.
The baseline survey was sent by mail and followed up with a
telephone interview for data collection. The survey began with a
cover letter from the principal investigator, followed by the
baseline CS-VAS, the EQ-5D-5L questionnaire, the EQ-5D ques-
tionnaire VAS, the SF-12v2 (the SF-6D derived from seven of the
SF-12 items), and demographic items.
Postprocedure
We aimed to contact patients for the second, posttest interview
not more than 4 days after the procedure. Given the variable
effects of sedation, attempted telephone contact began the day
after the procedure. The survey was similar to baseline except
that the TMI was also included, and the CS-VAS wording was
tailored to reﬂect the posttest assessment as follows: “We would
like you to rate the overall experience you had with colonoscopy
and its temporary effect on your quality of life. On a scale of 0 to
100, with 0 being the value of death and 100 being the value of
perfect health, please provide a number in the blank space below.
This rating would take into consideration the physical and/or
mental discomfort related to preparing for the procedure, the
procedure itself, and any discomfort after the procedure.” The
posttest survey was handed to patients who had completed the
baseline survey before leaving the hospital, to be followed by
telephone interview to obtain the survey data as above.
Design, Analysis, and Hypotheses
Given our theoretical model of testing, it is expected that in a
posttest assessment of the test process, HRQOL will have decreased
from baseline. The morbidity, however, is likely transient, again
motivating assessment as soon as possible after testing.
Measures of responsiveness are often variations of ES, includ-
ing baseline and postevent variability. Paired t tests, ES, and
standardized response mean (SRM) measures were included. For
example, using group data, the baseline EQ-5D-5L questionnaire
and postevent EQ-5D-5L questionnaire results were analyzed for
the SRM by using the difference in change scores/SD of change
scores. The SD of the baseline score is relevant for the denom-
inator of ES calculations [21]. Calculation of responsiveness forthe TMI focuses more on the SRM because there is no baseline
variability. The TMI structure makes typical ES calculations
infeasible, and the use of a pooled SD for ES is questionable
because baseline and postprocedure SDs are dissimilar. The TMI
SRM, however, may be inﬂated because of the invariable baseline.
Therefore, additional construct validation by Pearson correlations
of post–CS-VAS with TMI seemed advisable and also CS-VAS
correlation with standard indexes at baseline. Ceiling and ﬂoor
effects were calculated by the percentage of a group at the top
and bottom scores of an instrument and were illustrated in
normal plots.
At baseline, generic indexes and baseline CS-VAS were antici-
pated to have a correlation of at least 0.4. From our pilot work, a
correlation of postprocedure CS-VAS with TMI of at least 0.4 to 0.5
was expected. Substantive correlation of the EQ-5D-3L question-
naire and the SF-6D is known from the literature [33]. The SRM of
TMI was expected to be comparable to that of the CS-VAS (at least
moderate) and better than the generic indexes. Given the known
SF-6D low ceiling effect and recall period, the SF-6D was antici-
pated to be moderately responsive, with a greater SRM than that
of the EQ-5D questionnaire. Fifteen percent is a cited cutoff for
substantial ceiling effects [34,35]. In our preliminary work, we
used the TMI health classiﬁcation to evaluate 188 patients who
had breast biopsies prior to TMI completion. Nine patients gave
TMI results at the ceiling (all best possible levels for each of the
seven items), that is, a ceiling effect of 4.8%. Thus, we expected
that TMI and the CS-VAS would have a less than 15% ceiling
effect. From the literature, the SF-6D was expected to have a less
than 15% ceiling effect and the EQ-5D questionnaire was
expected to have a greater than 15% ceiling effect [26]. No ﬂoor
effects were anticipated. Medcalc v. 12.3.0 (Mariakerke, Belgium)
was used for analyses.
Before any analysis, a ﬁnal analysis group was designated
with interviews that had taken place 4 days or less after the
procedure. All patients with complete data, however, were later
analyzed to see whether the patients excluded caused any
substantive changes in our trends.Results
Table 2 shows study and procedural demographics. Response rate
was 55%, based on the number of overall completes (109) divided by
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 4 6 – 1 0 5 31050unreachable patients (107) þ completes (109) þ refusals (71) þ those
completing the preprocedure survey only (17) minus unreachable
patients (107). One patient emailed survey responses. Our response
rate uses as the numerator the number of patients who completed
both surveys and a denominator of those who were eligible to be
contacted for baseline and invited to participate, less those who
could never be contacted at baseline. Baseline interviews occurred
between 4 and 30 days before the colonoscopy procedure. All
patients had the surveys in front of them at the time of the
telephone interview (which included VAS instruments), these hav-
ing been mailed previously. Survey completion time was approx-
imately 5 to 7 minutes for patients.
Most patients provided all measures except for one who did not
complete the EQ-5D-5L questionnaire and the CS-VAS (Table 3). The
CS-VAS, TMI, and SF-6D showed an expected decrease from base-
line in the HRQOL, and thus had negative SRMs. The SF-6D change,
however, was minimal (all index or VAS values are rounded to two
places; mean SF-6D value was minimally less than the baseline
value of 0.87 at the postprocedure interview [0.8681]). The TMI
shows the largest SRM, with the CS-VAS the second largest, having
near-moderate SRM and moderate to large ES [36]. The EQ-5D-5L
questionnaire appears unresponsive, with the SRM and the ES
moderately positive and a signiﬁcant baseline to postprocedure
change. The EQ-5D questionnaire VAS is similar overall to the EQ-
5D-5L questionnaire but with a less positive trend. The SF-12v2 PCS
and MCS were unresponsive. Normal plots (Fig. 1A–E) show the
distribution and ceiling effects of the postprocedure assessments.
The TMI results show a smaller percentage of the group at the
ceiling than did other instruments. The TMI results were normally
distributed (D’Agostino-Pearson and Kolmogorov-Smirnov tests)
unlike others. The EQ-5D-5L questionnaire had the largest ceiling
effect. While the SF-6D had 14.1% at the ceiling, 41% of the group
had a utility of 0.92. No ﬂoor effects were noted.
For discussion of construct validity, strength of correlation
refers to Juniper et al. [37] in which moderate correlation is 0.35 to
0.5 and strong is deﬁned as more than 0.5, which is also
consistent with examples from De Vet et al. [38]. The baseline
CS-VAS correlated strongly with the SF-6D, the EQ-5D question-
naire, and the EQ-VAS questionnaire measures (r ¼ 0.54–0.81, all P
o 0.0001). Postcolonoscopy, the CS-VAS correlated strongly with
the TMI (r ¼ 0.52, P o 0.0001).
Figure 2 shows a breakdown of the TMI item score means with
95% conﬁdence intervals. The greatest morbidity is noted before the
actual procedure in the physical and mental domains/attributes.
Our supplemental analysis included the addition of 38 patients
(thus, n ¼ 109 total completes as noted above), all of whom could
not be contacted within 4 days. There was no change in basic
trends of interest. The EQ-5D questionnaire responsiveness was
similar (SRM 0.43), and the SF-6D was also unresponsive (SRM 0.08).
The CS-VAS was somewhat less responsive than in the ﬁnal group
(ES with baseline SD: 0.48, ES using pooled SD: 0.33, and SRM
0.25). The TMI remained highly responsive with an SRM of 1.46.
No substantive differences in correlations were noted.Discussion
The TMI summated scale version shows evidence of responsive-
ness in screening colonoscopy. Moderate responsiveness was
seen with the CS-VAS. Other instruments showed either no
evidence of responsiveness or minimal responsiveness. The
degree of responsiveness of the TMI and the CS-VAS was in line
with expectations, but the SF-6D was very minimally responsive,
contrary to expectations.
There was evidence of TMI construct validity, demonstrated
by correlation with the postprocedural VAS, meant to capture the
HRQOL effects of colonoscopy. The degree of correlation of the
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Fig. 1 – (A) Normal plot of the EQ-5D-5L questionnaire postcolonoscopy; 67.6% of the respondents were at the ceiling. No ﬂoor
effect is evident. (B) Normal plot of the EQ-5D questionnaire VAS postcolonoscopy; 16.9% of the respondents were at the
ceiling. No ﬂoor effect is noted. (C) Normal plot of the CS-VAS for overall effect of colonoscopy, postprocedure; 12.9% of the
respondents were at the ceiling. No ﬂoor effect was present. (D) Normal plot of SF-6D scores postcolonoscopy; 14.1% of the
respondents were at the ceiling. No ﬂoor effect is present; 40.9% of the respondent utilities were at 0.92. (E) Normal plot of the
TMI summated scale postcolonoscopy; 11.3% of the respondents were at the ceiling. No ﬂoor effect is noted. The TMI
summated scale (0–100) was converted to a 0 to 1.0 (worst to best) scale. EQ-5D, EuroQol ﬁve-dimensional; EQ-5D-5L
questionnaire, EuroQol ﬁve-dimensional questionnaire with ﬁve levels in each attribute; SF-6D, six-dimensional health utility
short form (derived from short-form 12v2 health survey); TMI, Testing Morbidities Index; VAS, visual analogue scale.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 4 6 – 1 0 5 3 1051TMI with the post–CS-VAS was in line with hypothesized esti-
mates based on pilot work. Baseline CS-VAS correlated well with
the generic instruments at baseline, as expected.
The TMI summated scale had the smallest ceiling effect. The
EQ-5D-5L questionnaire did not show a decreased tendency towardceiling effects as compared with the EQ-5D-3L questionnaire [24,26],
with 67.6% at postcolonoscopy, possibly inﬂuenced by the short
recall. The other instruments besides the EQ-5D questionnaire VAS
all showed ceiling effects postprocedure below the 15% cutoff. The
distribution of the TMI item scores (Fig. 2) is consistent with the
TMI Mean Item Scores: Screening Colonoscopy (n= 71)
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Fig. 2 – Plot of TMI item scores (1–5 response set). The mean for each item and 95% CI markers are plotted. Most morbidity is
captured in the bowel preparation and anxiety before the procedure. CI, conﬁdence interval; TMI, Testing Morbidities Index.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 4 6 – 1 0 5 31052clinical reality of colonoscopy. Morbidity is usually greatest in the
events before the actual test, due to the bowel preparation and
anxiety about the procedure, whereas problems are minimal during
the procedure because patients are variably sedated, and afterward,
most patients have few difﬁculties [39,40].
Although new instrument development is often discouraged
[41], it was suspected beforehand that existing indexes would not
tap into the speciﬁcs of testing morbidity, with the possible
exception of the SF-6D. The context of typical index items is
likely important, meaning that patients may think more about
how their life has been in general when answering items from a
generic index such as the SF-6D or others, and may disregard
short-term events because they do not make up “usual” HRQOL.
Comparison to the limited prior data in testing using the EQ-5D
questionnaire in breast biopsy is problematic because in both of
those studies, the pretest baseline is very close to the event (day
before or morning of biopsy) [22,23]. We contend that the time
immediately before a test is not a baseline, at least in terms of
psychological aspects, and in some tests such as colonoscopy,
physical aspects are relevant. A best baseline occurs before any of
the domains of the TMI classiﬁcation are in effect, and as stated
in the Methods section, such a baseline is probably the usual
HRQOL that is occurring before the test was even proposed by the
clinician to the patient. Both cited breast biopsy studies also used
a 4-day time frame for the ﬁrst posttest assessment, when short-
term effects may or may not be relevant. One study [22] acknowl-
edges that a true baseline is unmeasured. With a true baseline
likely at a much better level of HRQOL than an assessment right
before a biopsy, however, the validity of comparing an immediate
preprocedure baseline to an assessment after the procedure may
be problematic. With this in mind, the other study [23] noted a
minimal decrease between 1 day before and 4 days afterward
with the EQ-5D-3L questionnaire in breast needle biopsy, and no
change at all for the EQ-5D questionnaire VAS.
There were limitations to our study. A primary interest is the
calculation of responsiveness with the TMI. Because the structure
of the TMI classiﬁcation does not allow a usual baseline, the “best
possible test” (100 or 35 as described above) must serve as the
baseline for all patients. This assumption likely inﬂates the SRMmeasure. Nonetheless, the CS-VAS designed for baseline and
postprocedure (the latter meant to aggregate the testing experi-
ence overall) showed moderate responsiveness. Furthermore, the
TMI correlated strongly with the post–CS-VAS.
The potential effect of sample size is reasonable to consider with
this study. Such considerations are most important for the SF-6D,
which was expected to be responsive. Our sample size of 71,
however, is adequate for 96% to 99% power for the SF-6D, with the
assumption of 0.05 for the P value, and assuming a minimally
important difference of 0.036 (anchor-based [42]) and a one half SD
estimate of minimally important difference of 0.053 [42], respectively.
For this power assessment, we use the SD of the differences we
found between the baseline and postprocedure SF-6D assessments.
Given the variable temporal scheduling of patients before the
colonoscopy combined with frequent patient cancellations of the
procedure itself, we elected to focus on making certain that the
baseline interview would not overlap the bowel preparation.
Thus, we were stringent on the baseline occurring at least 3 days
before the bowel preparation (thus, 4 days before the procedure).
Interviews took place a maximum of 30 days beforehand, though
we did not document a mean number of days. This is a limitation
in that baseline assessments could conceivably vary relative to
how far away from the procedure they occur. Our baseline
assessments with the generic indexes and the baseline CS-VAS
for “usual quality of life,” however, were strongly correlated,
suggesting that we still captured baseline HRQOL.
The health utilities index (HUI) mark 2 and 3 was not used in
this study [43] given available resources for licensing fees and
potential respondent burden. The HUI may be unresponsive in
testing like the other indexes, but it may be worth conﬁrming
because the HUI versions have generally good performance and the
highest reliability coefﬁcients of the current standard indexes [26].
Further evaluation planned for the TMI includes assessment
of test-retest reliability and known-groups validity in multiple
testing scenarios that vary over the spectrum of invasiveness, as
well as implementation of a preference-based version.
The TMI shows initial evidence of responsiveness and addi-
tional evidence of construct validity, consistent with prior evi-
dence of construct and content validity [17]. Given continued
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 4 6 – 1 0 5 3 1053successful measures of reliability and validity as planned above,
outcomes assessments for small and large projects could possibly
be informed by the TMI. For example, TMI items could be
incorporated into studies of adherent and nonadherent screening
groups. To this end, we are pursuing research in which we have
written the TMI items in slightly different hypothetical language
for evaluating expected morbidities of testing in inexperienced
patients. Results from experienced patients in such a study could
be compared with those from nonadherent patients and used for
education of nonadherent groups. Similarly, our results could be
used to educate nonadherent patients about the experience of
colonoscopy. A repository of such information across various
tests could inform shared decision making and be leveraged for
quality assurance. Larger studies could use TMI data to inform
health initiatives on the perceived morbidity of current and
future procedures and to compare the morbidity of various tests
[1]. Finally, a TMI with preference weights might inform cost-
effectiveness analysis of diagnostic technologies. Together, all
these approaches may better assess testing with an additional
patient-centered focus.
Source of ﬁnancial support: Financial support for this study
was provided in part by grants from The American Cancer Society
(114130-RSGHP-07-266-01-CPHPS) and the MGH ECOR Bridge Fund
(1200-218421).
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